Hepatitis C


Book Description




Eliminating the Public Health Problem of Hepatitis B and C in the United States


Book Description

Hepatitis B and C cause most cases of hepatitis in the United States and the world. The two diseases account for about a million deaths a year and 78 percent of world's hepatocellular carcinoma and more than half of all fatal cirrhosis. In 2013 viral hepatitis, of which hepatitis B virus (HBV) and hepatitis C virus (HCV) are the most common types, surpassed HIV and AIDS to become the seventh leading cause of death worldwide. The world now has the tools to prevent hepatitis B and cure hepatitis C. Perfect vaccination could eradicate HBV, but it would take two generations at least. In the meantime, there is no cure for the millions of people already infected. Conversely, there is no vaccine for HCV, but new direct-acting antivirals can cure 95 percent of chronic infections, though these drugs are unlikely to reach all chronically-infected people anytime soon. This report, the first of two, examines the feasibility of hepatitis B and C elimination in the United States and identifies critical success factors. The phase two report will outline a strategy for meeting the elimination goals discussed in this report.




Hepatitis C-What You Need to Know!


Book Description

All your questions answered about hepatitis C! From diagnosis to treatment and other important information you need to know about hepatitis C.




Hepatitis C


Book Description

The virus that causes hepatitis C mostly damages the liver by inflaming it and perhaps causing long-term damage. HCV (Hepatitis C virus) is the name of the virus that causes hepatitis C. A thorough explanation of hepatitis C is provided below: Crucial Points: Transmission: Contact with an infected person's blood is the main way that hepatitis C is spread. Common means of transmission include intravenous drug users sharing needles, risky medical procedures, and getting tainted blood or blood products prior to the implementation of broad screening programs. Prolonged Infection: Acute and chronic infections can result from hepatitis C. A chronic infection is one that lasts over time, however some people may be able to overcome the virus on their own during the acute phase. inflammation of the liver: Inflammation results from the virus's targeting of liver cells. Long-term liver cirrhosis, liver fibrosis, and an elevated risk of liver cancer can result from chronic hepatitis C, even though it might grow silently for years without showing any signs. Manifestations: An acute hepatitis C infection may show no symptoms at all or only very mild ones. It's possible that extensive liver damage from chronic hepatitis C won't show any signs at first. Joint discomfort, weariness, jaundice, and stomach ache are possible sym




Hepatitis and Liver Cancer


Book Description

The global epidemic of hepatitis B and C is a serious public health problem. Hepatitis B and C are the major causes of chronic liver disease and liver cancer in the world. In the next 10 years, 150,000 people in the United States will die from liver disease or liver cancer associated with chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infections. Today, between 800,000 and 1.4 million people in the United States have chronic hepatitis B and between 2.7 and 3.9 million have chronic hepatitis C. People most at risk for hepatitis B and C often are the least likely to have access to medical services. Reducing the rates of illness and death associated with these diseases will require greater awareness and knowledge among health care workers, improved identification of at-risk people, and improved access to medical care. Hepatitis B is a vaccine-preventable disease. Although federal public health officials recommend that all newborns, children, and at-risk adults receive the vaccine, about 46,000 new acute cases of the HBV infection emerge each year, including 1,000 in infants who acquire the infection during birth from their HBV-positive mothers. Unfortunately, there is no vaccine for hepatitis C, which is transmitted by direct exposure to infectious blood. Hepatitis and Liver Cancer identifies missed opportunities related to the prevention and control of HBV and HCV infections. The book presents ways to reduce the numbers of new HBV and HCV infections and the morbidity and mortality related to chronic viral hepatitis. It identifies priorities for research, policy, and action geared toward federal, state, and local public health officials, stakeholder, and advocacy groups and professional organizations.




Guidelines on Hepatitis B and C Testing


Book Description

Testing and diagnosis of hepatitis B (HBV) and C (HCV) infection is the gateway for access to both prevention and treatment services, and is a crucial component of an effective response to the hepatitis epidemic. Early identification of persons with chronic HBV or HCV infection enables them to receive the necessary care and treatment to prevent or delay progression of liver disease. Testing also provides an opportunity to link people to interventions to reduce transmission, through counselling on risk behaviors and provision of prevention commodities (such as sterile needles and syringes) and hepatitis B vaccination. These are the first WHO guidelines on testing for chronic HBV and HCV infection and complement published guidance by WHO on the prevention, care and treatment of chronic hepatitis C and hepatitis B infection. These guidelines outline the public health approach to strengthening and expanding current testing practices for HBV and HCV, and are intended for use across age groups and populations.




100 Questions & Answers about Hepatitis C


Book Description

There are approximately 2.5 million cases of Hepatitis C in the United States and approximately 200 million worldwide. Whether you're a newly diagnosed patient, a friend or relative of someone with Hepatitis C, this book offers help. Written by two physicians from Lahey Clinic Medical Center, Dr. Fabry and Dr. Narasimhan, this book provides authoritative, practical answers to the most common questions about Hepatitis C.




Hepatitis C


Book Description

Vital and hopeful information for people suffering from hepatitis C, an often chronic—and sometimes deadly—disease of the liver. The liver is the body's workhorse. It makes proteins and bile, processes fats, and detoxifies drugs and alcohol. The liver is a resilient organ, but it is susceptible to damage from a number of sources, including viral infections. Such infections cause inflammation of the liver, called hepatitis. This book is a comprehensive guide to hepatitis C, which affects about 3 percent of the world's population—3 to 4 million people in the United States alone. Some people with acute hepatitis C infection will be cured without any treatment, but when hepatitis C becomes chronic it may cause cirrhosis, liver cancer, and death. Hepatitis C is transmitted from an infected person to an uninfected person by sharing drug-injecting equipment, snorting cocaine, having sex, or getting a blood transfusion or organ transplant. It can be spread by getting a tattoo with unsterile equipment. In rare cases, women with hepatitis C transmit the virus to their infants. World-renowned gastroenterologist and liver specialist Dr. Paul J. Thuluvath provides detailed information about the disease and its diagnosis and management, including dramatically improved treatments that have recently emerged. Dr. Thuluvath answers common and uncommon questions about hepatitis C and liver disease, including How is hepatitis C spread? Who should be tested—and what tests diagnose hepatitis C and other liver diseases? What are the symptoms of acute liver disease? What are the symptoms and complications of chronic liver disease? What are the complications of cirrhosis (scarring of the liver)? How does hepatitis C affect other organs in the body? What treatment options are available, and what side effects might they have? How is early liver cancer diagnosed and treated? When is liver transplantation needed, and how does it work? Dr. Thuluvath provides the latest information on new interferon-free regimens, which have shown a cure rate of more than 90% in people with specific genotypes—and which avoid the distressing side effects of interferon therapy. He discusses hepatitis C in children as well as complementary and alternative medicine. Published while revolutionary changes are taking place in the treatment of hepatitis C, this authoritative guide will become the preferred reference for people with hepatitis C and their families.




Free from Hepatitis C


Book Description

For decades, having hepatitis C virus (HCV) was the equivalent of serving a life sentence—with a dangerous liver disease. All of that changed with the discovery that the virus could be defeated with a new treatment. To shed light on this groundbreaking therapy, Lucinda Porter, a registered nurse, a passionate HCV advocate, and a hep C patient herself, has written a comprehensive guide for people who are undergoing or considering this new hep C treatment. Ms. Porter begins by explaining what hepatitis C is. She then looks at both the mainstream and the alternative management techniques currently used to keep the virus in check. From there, she examines hep C’s new therapy and what you can expect from it. The author demystifies test results, provides important questions you can ask your healthcare provider, and offers advice—all with the compassion of someone who has gone through the process herself. Well over 3 million North Americans live with hepatitis C. Here, at last, is all the information they need to make informed decisions about their future.